Deep Remission in Inflammatory Bowel Disease: Looking Beyond Symptoms

Authors :: Camille Zallot
Laurent Peyrin-Biroulet
Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)
Service d'Hépato-gastro-entérologie [CHRU Nancy]
Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
Source :: Current Gastroenterology Reports, Current Gastroenterology Reports, Current Medicine Group, 2013, 15 (3), ⟨10.1007/s11894-013-0315-7⟩
Publication Year :: 2013
Publisher :: Springer Science and Business Media LLC, 2013.
Abstract: International audience; Inflammatory bowel diseases (IBD) are chronic and disabling conditions. Accumulating evidence indicates that we need to look beyond clinical symptoms as current therapeutic strategies have not modified the course of IBD. Therapeutic goals for IBD have evolved from a mere control of symptoms to mucosal healing (MH). Achieving deep remission (clinical remission, biomarker remission and MH) might be the only way to alter disease course in IBD patients. In Crohn’s disease (CD), deep remission has been recently defined as Crohn’s Disease Activity Index

Tools